XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.25.3

FINANCIAL INSTRUMENTS AT FAIR VALUE | 9 Months Ended
--- | ---
Sep. 30, 2025
Investments, All Other Investments [Abstract] |
FINANCIAL INSTRUMENTS AT FAIR VALUE | NOTE 8: FINANCIAL INSTRUMENTS AT FAIR VALUE Financial instruments: The Company has financial instruments measured at level 3 arising from the June 2024 Facility Agreement, the First July 2024 Facility Agreement and the Second July 2024 Facility Agreement (see notes 7.E, 7.F, 7.G). Embedded derivatives were identified and recognized at fair value upon initial recognition of each of the financial instruments and measured at fair value at each balance sheet date. The fair value of the financial instruments as of December 31, 2024, was calculated using the following unobservable inputs: share price: $0.472, expected volatility: 148%, exercise price: $1.00, risk-free interest rate: 4.24%-4.32%, expected life: 0.46-0.50 years. On June 5, 2025, immediately after the Uplist, the Company converted all embedded derivatives to equity. At the Uplist Date and before the conversion, these embedded derivatives were measured at their intrinsic value through profit or loss. The following table presents the financial instruments that were measured at fair value through profit or loss: SCHEDULE OF FINANCIAL INSTRUMENTS
|  | Embedded derivatives |
Balance as of January 1, 2025 |  |  | 29 |
Net changes at fair value recognized through profit or loss |  |  | 10,121 |
Embedded derivatives converted to equity |  |  | (10,150 | )
Embedded derivatives recorded in connection with the June 2024 Facility Agreement, the First July 2024 Facility Agreement and the Second July 2024 Facility Agreement |  |  |  |
Warrants issued to the June 2024 Lead Lender (see note 7.E) |  |  |  |
Reclassification of derivative warrant liability into equity (see note 7.E) |  |  |  |
Balance as of September 30, 2025 |  |  | - |
|  | Embedded derivatives |
Balance as of January 1, 2024 |  |  | - |
Embedded derivatives, Balance |  |  | - |
Embedded derivatives recorded in connection with the June 2024 Facility Agreement, the First July 2024 Facility Agreement and the Second July 2024 Facility Agreement |  |  | 40 |
Warrants issued to the June 2024 Lead Lender (see note 7.E) |  |  | 1,833 |
Reclassification of derivative warrant liability into equity (see note 7.E) |  |  | (1,833 | )
Net changes at fair value recognized through profit or loss |  |  | (11 | )
Balance as of December 31, 2024 |  |  | 29 |
Embedded derivatives, Balance |  |  | 29 |
VIEWBIX INC. NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) U.S. dollars in thousands (except share data)

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/825/tableOfContent + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAllOtherInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration